SRPT : Analysis & Opinions

  1. Sarepta Therapeutics One Step Closer to Drug Approval

    July 3, 2015
    Analysts are optimistic about the future of Sarepta as the biotechnology company submits a New Drug Application the FDA.
  2. Sarepta Gets FDA Green Light to Submit Application (SRPT, BMRN)

    May 20, 2015
    It's not often you see a biotech soar more than 60% after announcing plans to submit a marketing application to the Food ...
  3. Sarepta Earnings Preview: 3 Things to Watch For (SRPT)

    May 4, 2015
    Since the stock peaked at more than $55 per share in October 2013, Sarepta Therapeutics' (NASDAQ: SRPT) shareholders have ...
  4. Sarepta Therapeutics' 3 Biggest Risks (SRPT)

    March 23, 2015
    There are arguably few diagnoses as frightening for children and their parents as Duchenne muscular dystrophy, or DMD. Based ...
  5. Should We Be Concerned For Sarepta’s Share Prices? (SRPT)

    March 2, 2015
    The disease that's caught the attention of a few biotech companies, including Sarepta Therapeutics , is Duchenne muscular ...
  6. A Look Back At The Year In Biotech

    December 28, 2012
    Biotech stocks have been major outpeformers in 2012.
  7. Alexion Pharmaceuticals and More Big Movers in Healthcare on ...

    December 7, 2012
    So far today, the Nasdaq is down 0.7%, the S&P 500 is unchanged and the Dow is trading up 0.3%. The healthcare sector ...
Trading Center